This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Health IT company Veradigm eliminated 15% of its total workforce in 2025, executives said during a business update on Wednesday. “These decisions are the toughest ones you make as a leader, and we work very hard to be thoughtful in our approach,” CEO Don Trigg said during the call with investors on its estimated financial results and strategic focus for 2026. ...

Financial Data and Key Metrics Changes - In Q4 2025, global sales from continuing operations totaled $3 billion, representing an 8% increase on a reported basis and a 3% increase on an operational basis [8][17] - Adjusted earnings from continuing operations were $0.44 per diluted share, which fell short of expectations despite exceeding top-line forecasts [8][17] - Adjusted gross margins from continuing operations were 35.5%, a decrease of 900 basis points compared to the prior year [25] - Adjusted operating margin from continuing operations was 11.8%, a decrease of 340 basis points compared to the prior year [26] Business Line Data and Key Metrics Changes - Medical Products and Therapies (MPT) segment sales were $1.4 billion, increasing 4% in the quarter, driven by growth in Infusion Therapies and Technologies [17][18] - Advanced Surgery products grew 11%, totaling $328 million, reflecting strong demand and commercial execution [10][19] - Healthcare Systems and Technologies (HST) sales totaled $827 million, increasing 4%, with Care and Connectivity Solutions growing 4% globally [20] - Pharmaceuticals segment sales were $668 million, increasing 2%, but the injectables and anesthesia division saw a decline of 9% [21][22] Market Data and Key Metrics Changes - U.S. capital orders for Care and Connectivity Solutions increased nearly 30% compared to the prior year, indicating strong demand in the market [20] - The company has not observed a slowdown in U.S. hospital capital spending, although broader macroeconomic uncertainty is being monitored [20] Company Strategy and Development Direction - The company is focused on three main priorities: stabilizing the business, strengthening the balance sheet, and driving a culture of continuous improvement [11][12] - A new operating model has been announced to simplify the organization, accelerate innovation, and improve performance by delayering leadership and embedding critical functional roles [12][60] - Innovation is emphasized as a critical element for success, with continued investment in R&D at or above historical levels [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced and emphasizes the need for improvement in performance and execution [9] - The outlook for 2026 anticipates total sales growth to be flat to 1% on a reported basis, with organic sales growth expected to be approximately flat [29][31] - The first quarter of 2026 is expected to be the most challenging, with improvements anticipated in the second half of the year [34] Other Important Information - Free cash flow generation exceeded $450 million in Q4 2025, with full-year free cash flow at $438 million [28] - The company plans to deploy cash towards reducing leverage in line with its capital allocation framework [28] Q&A Session Summary Question: Strategic review and sustainability of the business - Management emphasized the importance of accountability at lower levels and the need for continuous improvement to enhance performance [38][39] Question: Progress on reducing G&A and support costs - Management confirmed that they are on track with cost takeout and streamlining operations to meet demand, with a commitment to eliminate stranded costs by the end of 2027 [44][45] Question: Earnings growth as TSAs roll off - Management anticipates growth but has not provided specific guidance for 2027, as TSAs will tail off in early 2027 [48][49] Question: Q4 gross margin decline - Management attributed the decline to unfavorable sales mix, higher manufacturing costs, and non-recurring items, with expectations for improvement in the second half of 2026 [68][72] Question: Improving margins in the pharmaceuticals business - Management expressed confidence in the fundamentals of the pharmaceuticals business and outlined actions being taken to improve operational execution and address supplier challenges [76][78]

Financial Data and Key Metrics Changes - In Q4 2025, global sales from continuing operations totaled $3 billion, representing an 8% increase on a reported basis and a 3% increase on an operational basis [7][16] - Adjusted earnings from continuing operations were $0.44 per diluted share, which fell short of expectations despite exceeding top-line forecasts [7][16] - Adjusted gross margins from continuing operations were 35.5%, a decrease of 900 basis points compared to the prior year [24] - Adjusted operating margin from continuing operations was 11.8%, a decrease of 340 basis points compared to the prior year [25] Business Line Data and Key Metrics Changes - Medical Products and Therapies (MPT) segment sales were $1.4 billion, increasing 4% in the quarter, driven by growth in Infusion Therapies and Technologies [17][19] - Advanced Surgery products grew 11% to $328 million, reflecting strong demand and commercial execution [19] - Healthcare Systems and Technologies (HST) sales totaled $827 million, increasing 4%, with Care and Connectivity Solutions growing 4% globally [20] - Pharmaceuticals segment sales were $668 million, increasing 2%, but injectables and anesthesia division sales declined 9% [21][22] Market Data and Key Metrics Changes - U.S. capital orders for Care and Connectivity Solutions increased nearly 30% compared to the prior year, indicating strong demand [20] - The overall market for IV solutions remains below historical levels, influenced by fluid conservation practices following Hurricane Helene [18] Company Strategy and Development Direction - The company is focused on three main priorities: stabilizing business areas, strengthening the balance sheet, and driving a culture of continuous improvement [11] - A new operating model has been announced to simplify the organization, accelerate innovation, and improve performance by delayering leadership and embedding critical functional roles [12][60] - Innovation is emphasized as a critical element for success, with continued investment in R&D at or above historical levels [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges ahead and emphasizes the need for improvement in performance and execution [8][9] - The company expects total sales growth for 2026 to be flat to 1% on a reported basis, with organic sales growth expected to be approximately flat [28][29] - The first quarter of 2026 is anticipated to be the most challenging, with expectations for improvement in the second half of the year [32][34] Other Important Information - Free cash flow generation exceeded $450 million in Q4 2025, with full-year free cash flow at $438 million [27] - The company plans to deploy cash towards reducing leverage in line with its capital allocation framework [27] Q&A Session Summary Question: What is being done to ensure sustainability of the business amid competitive dynamics? - Management is focusing on stabilizing the business, strengthening the balance sheet, and driving continuous improvement to enhance customer support and execution [36][39] Question: What progress is being made on reducing G&A and support costs related to the TSA? - The company is on track with cost takeout and streamlining operations, with a commitment to eliminate stranded costs by the end of 2027 [42][44] Question: Will earnings grow next year as TSAs roll off? - While growth is anticipated, specific guidance is not provided at this time [48] Question: What factors contributed to the decline in gross margins? - The decline was attributed to unfavorable sales mix, higher manufacturing costs, and non-recurring items totaling around $40 million [66][68] Question: What actions are being taken to improve margins in the pharmaceuticals business? - The company is focusing on operational execution and addressing supplier challenges to improve performance in the pharmaceuticals segment [73][75]

Core Viewpoint - Kering shares surged as the company reported results that were weak but better than feared, indicating a potential turnaround under new CEO Luca de Meo [1][6] Financial Performance - Fourth quarter revenue fell 3% year on year to €3.9 billion, surpassing expectations for a steeper decline [2] - Gucci, Kering's largest brand, experienced a 10% revenue decline to €1.6 billion, marking its tenth consecutive quarterly fall but slightly better than forecasts [3] - For the full year 2025, group revenue decreased 10% to €14.7 billion, and operating income dropped 33% to €1.6 billion, indicating a second consecutive year of double-digit profit declines [4] Strategic Changes - CEO Luca de Meo, who joined from Renault, stated that 2025 does not reflect Kering's true potential and described recent sales momentum as early and fragile but real [5] - The company proposed cutting its dividend to €4 per share from €6 the previous year, including a €1 special dividend linked to the sale of its beauty business to L'Oréal for €4 billion [5] - Kering confirmed plans to close around 100 more stores in 2026 after shutting 75 last year [5] Market Reaction - The market's positive reaction reflects a reset of expectations rather than a fundamental recovery, as Kering's share price had fallen over 50% in the past three years [6] - Investors appear to be optimistic about de Meo's leadership, as he has openly acknowledged past mistakes and emphasized the need for a more realistic approach to the company's challenges [7]

Core Insights - The healthcare giant experienced an 8% increase in revenue during the fourth quarter [1] Financial Performance - Revenue growth of 8% in the fourth quarter indicates strong performance [1]

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $149 million, up 1% reported but down 1% organically, with a 2% headwind from foreign exchange [14][16] - Non-GAAP EPS for the first quarter was $0.09, and adjusted EBITDA margin was 8.5%, down approximately 230 basis points year-over-year [15][17] - Free cash flow for the quarter was $15 million, with cash, cash equivalents, and marketable securities totaling $571 million, an increase of $25 million quarter-over-quarter [15][16] Business Line Data and Key Metrics Changes - In Sample Management Solutions, revenue was $81 million, flat on a reported basis and down 2% organically, with growth in biorepositories offset by declines in automated stores and cryo [18][19] - Multiomics revenue was $67 million, up 1% on a reported basis and flat organically, with growth in next-generation sequencing and gene synthesis, but weakness in Sanger sequencing [19][20] - Gross margin for Sample Management Solutions was 45.4%, down 370 basis points year-over-year, primarily due to higher rework costs on automated stores projects [19] Market Data and Key Metrics Changes - Positive momentum was observed in Europe, while North America remained slow, impacted by macroeconomic conditions and a government shutdown [6][8] - China showed strong performance with 26% organic growth in Multiomics, driven by demand in biotech and pharma [20][77] - The overall market conditions are mixed, with cautious capital spending decisions across parts of the life sciences ecosystem [6][8] Company Strategy and Development Direction - The company aims to embed operational excellence, accelerate growth, and expand margins as part of its strategic priorities for 2026 [6][11] - A definitive agreement for the sale of B Medical was announced, expected to close by March 31, 2026, which will sharpen focus on core portfolio and enhance financial flexibility [11][14] - The company is committed to disciplined capital deployment and has a $250 million share repurchase authorization to return value to shareholders [11][16] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improvements in capital markets and renewed M&A activity, expecting greater clarity around government and academic funding [6][8] - The company anticipates acceleration in the second half of 2026 as delayed approvals are processed and capital investment ramps up [9][13] - Management remains confident in achieving full-year guidance of 3%-5% organic revenue growth and adjusted EBITDA margin expansion of approximately 300 basis points [13][22] Other Important Information - The company continues to focus on operational improvements through the Azenta Business System, which drives measurable improvements in delivery, quality, and productivity [10] - The company is addressing quality issues in automated stores, with remediation efforts expected to be completed by the end of Q2 [19][64] Q&A Session Summary Question: Can you discuss your confidence in getting SMS margins back to desired levels? - Management acknowledged product mix and geo mix causing margin headwinds but expressed confidence in addressing these issues and reiterated guidance for the full year [24][25] Question: What are your expectations for top-line performance in Q2? - Management indicated that while they do not guide quarterly, they expect an uplift in revenue compared to Q1, with significant growth anticipated in the second half of the year [41][42] Question: How are you addressing the quality issues in automated stores? - Management detailed efforts to resolve quality issues and emphasized structural alignment to better serve customers, indicating that they are on track to meet customer needs [64][66] Question: What is the outlook for growth in the pharma and biotech sectors? - Management noted increased clarity and confidence in the pharma and biotech sectors, with ongoing investments and positive conversations with customers [49][50]

Core Viewpoint - Siemens Energy's CEO acknowledged the legitimacy of activist investor Ananym Capital's call for a spin-off of its unprofitable wind turbine division, emphasizing the need for the business to be stabilized and turned around first [1] Group 1 - The CEO's statement reflects a recognition of shareholder concerns regarding the performance of the wind turbine division [1] - The company is currently focused on stabilizing the wind turbine business before considering any structural changes such as a spin-off [1]

Core Viewpoint - United Parcel Service (UPS) is undergoing a significant business turnaround after experiencing a decline in stock value, with early signs of improvement in its operations and financial metrics [1][6]. Group 1: Business Operations - UPS operates a complex, capital-intensive package delivery service, which includes a vast network of retail stores, sorting and distribution facilities, and a large fleet of delivery vehicles [2]. - The company has been focusing on streamlining operations and prioritizing more profitable customers, which includes reducing reliance on Amazon, a key customer with low profit margins [4][5]. Group 2: Financial Performance - In the second quarter of 2025, UPS reported a 5.5% increase in revenue per piece in the U.S. market, despite a 0.8% decline in overall revenue for that division [7]. - The third quarter showed further improvement, with revenue per piece in the U.S. jumping 9.8% while overall revenue fell 2.6%, and the adjusted operating margin improved by 110 basis points year over year [8]. Group 3: Market Reaction - UPS's share price has increased by 24% over the past three months, indicating that investors are optimistic about the company's turnaround efforts [9]. - The current stock price is around $107.98, with a market capitalization of $92 billion and a dividend yield of 6.08%, although the dividend payout ratio exceeds 100% [8][10].

Flash | 22 Jan 2026 21:15:10 ET │ 11 pages MicroPort Scientific (0853.HK) FY25 Profit Alert: Strong Beat CITI'S TAKE MicroPort announced a significant positive profit alert for FY25, guiding for a net profit of at least US$20mn. This represents a strong beat versus our estimate of a US$54mn loss and VA consensus of a US$57mn loss, and marks a dramatic turnaround from the US$268mn loss in FY24. The strong result is driven by a combination of sustained revenue growth (led by the 'going-abroad' business at +70 ...

Group 1 - United Parcel Service (UPS) stock has decreased by 53% from its 2022 highs, but has seen a nearly 30% increase over the past three months, with a dividend yield of 6.1% [1] - UPS is one of the largest package delivery companies in the United States, requiring significant infrastructure for successful operations [2] - The company operates a vast network of distribution and sorting facilities, along with transportation assets, supported by a complex computer system for package tracking [3] Group 2 - UPS's reliable and quick package delivery service is a significant achievement, making it difficult for competitors to dislodge the company [4] - Amazon is a crucial customer for UPS, but the low profit margins from this business have led UPS to reduce the number of Amazon packages it handles as part of a larger overhaul focusing on higher-margin businesses [5] - Wall Street's concerns about UPS are reflected in the stock price decline since 2022, as the turnaround efforts involve increased spending and lower revenue [6] - UPS is working to streamline operations and improve profitability, with early signs indicating that the turnaround efforts are beginning to take effect [7]